| 1 |
Pinke KH, Zorzella-Pezavento SFG, Lara VS, Sartori A. Should mast cells be considered therapeutic targets in multiple sclerosis? Neural Regen Res 2020;15:1995-2007. [PMID: 32394947 DOI: 10.4103/1673-5374.282238] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 2 |
Meier UC, Cipian RC, Karimi A, Ramasamy R, Middeldorp JM. Cumulative Roles for Epstein-Barr Virus, Human Endogenous Retroviruses, and Human Herpes Virus-6 in Driving an Inflammatory Cascade Underlying MS Pathogenesis. Front Immunol 2021;12:757302. [PMID: 34790199 DOI: 10.3389/fimmu.2021.757302] [Reference Citation Analysis]
|
| 3 |
Choi JY, Yun J, Hwang CJ, Lee HP, Kim HD, Chun H, Park PH, Choi DY, Han SB, Hong JT. (E)-2-methoxy-4-(3-(4-methoxyphenyl) prop-1-en-1-yl) Phenol Ameliorates MPTP-Induced Dopaminergic Neurodegeneration by Inhibiting the STAT3 Pathway. Int J Mol Sci 2019;20:E2632. [PMID: 31146332 DOI: 10.3390/ijms20112632] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 4 |
Ahmad SF, Ansari MA, Nadeem A, Bakheet SA, Alshammari MA, Attia SM. Protection by tyrosine kinase inhibitor, tyrphostin AG126, through the suppression of IL-17A, RORγt, and T-bet signaling, in the BTBR mouse model of autism. Brain Research Bulletin 2018;142:328-37. [DOI: 10.1016/j.brainresbull.2018.08.020] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 5 |
Kaviarasi S, Yuba E, Harada A, Krishnan UM. Emerging paradigms in nanotechnology for imaging and treatment of cerebral ischemia. Journal of Controlled Release 2019;300:22-45. [DOI: 10.1016/j.jconrel.2019.02.031] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 6 |
Ahmad SF, Ansari MA, Nadeem A, Bakheet SA, Alsanea S, Al-Hosaini KA, Mahmood HM, Alzahrani MZ, Attia SM. Inhibition of tyrosine kinase signaling by tyrphostin AG126 downregulates the IL-21/IL-21R and JAK/STAT pathway in the BTBR mouse model of autism. Neurotoxicology 2020;77:1-11. [PMID: 31811869 DOI: 10.1016/j.neuro.2019.12.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 7 |
Carnero Contentti E, Correale J. Bruton's tyrosine kinase inhibitors: a promising emerging treatment option for multiple sclerosis. Expert Opin Emerg Drugs 2020;25:377-81. [PMID: 32910702 DOI: 10.1080/14728214.2020.1822817] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 8 |
Geladaris A, Häusler D, Weber MS. Microglia: The Missing Link to Decipher and Therapeutically Control MS Progression? Int J Mol Sci 2021;22:3461. [PMID: 33801644 DOI: 10.3390/ijms22073461] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 9 |
García-Merino A. Bruton's Tyrosine Kinase Inhibitors: A New Generation of Promising Agents for Multiple Sclerosis Therapy. Cells 2021;10:2560. [PMID: 34685540 DOI: 10.3390/cells10102560] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 10 |
Almalki WH, Alghamdi S, Alzahrani A, Zhang W. Emerging paradigms in treating cerebral infarction with nanotheranostics: opportunities and clinical challenges. Drug Discov Today 2021;26:826-35. [PMID: 33383212 DOI: 10.1016/j.drudis.2020.12.018] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 11 |
Pryce G, Baker D. Oligoclonal bands in multiple sclerosis; Functional significance and therapeutic implications. Does the specificity matter? Multiple Sclerosis and Related Disorders 2018;25:131-7. [DOI: 10.1016/j.msard.2018.07.030] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 4.5] [Reference Citation Analysis]
|
| 12 |
Giovannoni G, Popescu V, Wuerfel J, Hellwig K, Iacobeus E, Jensen MB, García-domínguez JM, Sousa L, De Rossi N, Hupperts R, Fenu G, Bodini B, Kuusisto H, Stankoff B, Lycke J, Airas L, Granziera C, Scalfari A. Smouldering multiple sclerosis: the ‘real MS’. Ther Adv Neurol Disord 2022;15:175628642110667. [DOI: 10.1177/17562864211066751] [Reference Citation Analysis]
|
| 13 |
Häusser-Kinzel S, Weber MS. The Role of B Cells and Antibodies in Multiple Sclerosis, Neuromyelitis Optica, and Related Disorders. Front Immunol 2019;10:201. [PMID: 30800132 DOI: 10.3389/fimmu.2019.00201] [Cited by in Crossref: 44] [Cited by in F6Publishing: 35] [Article Influence: 14.7] [Reference Citation Analysis]
|
| 14 |
Martin E, Aigrot MS, Grenningloh R, Stankoff B, Lubetzki C, Boschert U, Zalc B. Bruton's Tyrosine Kinase Inhibition Promotes Myelin Repair. Brain Plast 2020;5:123-33. [PMID: 33282676 DOI: 10.3233/BPL-200100] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
